Skip to main content

Table 3 Comparison of immunization effects on intrauterine and extrauterine prevention in newborns of HBsAg- and/or HBeAg-positive women 1)

From: Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials

Pregnancy infection status Newborn infection status Detective time Number of included studies Sample size Meta-RR (95% CI)
Total (HBsAg+ and/or HBeAg+) HBsAg+ At birth 23 4274 0.36(0.28, 0.45) 2)
7-12 month 8 1036 0.34(0.22, 0.53) 2)
>12 month 1 153 0.33(0.01, 7.95)2)
HBsAb+ At birth 7 1094 2.42(1.46, 4.01) 2)
7-12 month 6 757 1.12(1.00, 1.24)2)
>12 month 1 153 1.07(0.86, 1.33)2)
Subgroup (HBsAg+ and HBeAg+) HBsAg+ At birth 21 2159 0.40(0.32, 0.51) 2)
7-12 month 8 812 0.37(0.23, 0.57) 3)
>12 month 1 153 0.33(0.01, 7.95)2)
HBsAb+ At birth 7 909 3.05(2.19, 4.25) 2)
7-12 month 6 614 1.15(0.99, 1.34)2)
>12 month 1 153 1.07(0.86, 1.33)2)
Subgroup (HBsAg+ and HBeAg-) HBsAg+ At birth 15 1892 0.22(0.14, 0.35) 3)
7-12 month 4 224 0.22(0.06, 0.84) 3)
HBsAb+ At birth 3 185 1.31(0.82, 2.10)3)
7-12 month 3 148 1.09(0.97, 1.22)3)
Subgroup (low+unclear bias) HBsAg+ At birth 12 1945 0.35(0.22,0.54) 2)
7-12 month 5 643 0.52(0.30,0.91) 3)
>12 month 1 153 0.33(0.01,7.95)3)
HBsAb+ At birth 6 980 3.02(1.48,6.15) 2)
7-12 month 5 643 1.04(0.98,1.10)3)
>12 month 1 153 1.07(0.86,1.33)3)
Subgroup (high risk bias) HBsAg+ At birth 11 2329 0.37(0.29,0.47) 3)
7-12 month 3 393 0.18(0.08,0.39) 3)
HBsAb+ At birth 1 114 1.60(1.26,2.03) 3)
7-12 month 1 114 1.49(1.23,1.81) 2)
  1. 1)(Mother: HBIG/Infants: HBIG + vaccine) vs (Mother: none/Infants: HBIG + vaccine); 2)Random effects model, inverse variance method; 3)Fixed effects model, Mantel-Haenszel method; values in boldface indicate statistical significance (P < 0.05).
\